Atrial-fibrillation, or a-fib, affects nearly 2.5 million patients in the US, and is one of the more common forms of arrhythmia. The antiarrhythmic armamentarium has been expanded to include dronedarone, which was recently approved by the FDA for the treatment of a-fib. What's the efficacy and safety of dronedarone, compared to other antiarrhythmic agents, and how should you use it? Dr. Sanjay Kaul, director of the Vascular Physiology and Thrombosis Research Laboratory at the Burns and Allen Research Institute at Cedars-Sinai Medical Center in Los Angeles, describes the profile of patients who should be considered candidates for dronedarone therapy. Will dronedarone replace the current gold standard for treating a-fib, amiodarone, and if not, where does dronedarone fit into the management algorithm for a-fib? Dr. Janet Wright hosts.
Produced in Cooperation with
